Physician profile
Max E Lewis
NPI 1750606125
$15,366.94
in general payments reported to CMS, 2019-2025
78 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,586 · 2020: $1,873 · 2021: $2,272 · 2022: $2,043 · 2023: $2,300 · 2024: $2,090 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,424 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,423.60 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,256.09 | 2021-2025 | |
| Novo Nordisk INC | $1,477.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,232.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,104.27 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $871.95 | 2019-2025 | |
| Amgen INC. | $831.86 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $616.58 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $542.05 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $538.12 | 2019-2025 | Xarelto, Spravato |
| Astellas Pharma US INC | $482.72 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $391.29 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $384.07 | 2019-2025 | Rexulti |
| Harmony Biosciences LLC | $358.49 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $312.48 | 2019-2024 | Xywav |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.44 | 2019-2023 | Jardiance |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.